Archemix Corp.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 2000-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.archemix.com
Effect of ARC1779 on Cerebral Microembolism in Patients Undergoing Carotid Endarterectomy
Phase 2
Terminated
- Conditions
- Intracranial EmbolismCerebral ThromboembolismCarotid Stenosis
- Interventions
- Drug: ARC1779 InjectionDrug: Placebo (normal saline)
- First Posted Date
- 2008-08-27
- Last Posted Date
- 2010-02-10
- Lead Sponsor
- Archemix Corp.
- Target Recruit Count
- 100
- Registration Number
- NCT00742612
- Locations
- 🇺🇸
Eddy Scurlock Stroke Center - Methodist Hospital, Houston, Texas, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
🇬🇧Addenbrooke's Hospital, Department of Vascular Surgery, Cambridge, United Kingdom
Clinical Outcome Study of ARC1779 Injection in Patients With Thrombotic Microangiopathy
Phase 2
Terminated
- Conditions
- Thrombotic MicroangiopathyThrombotic Thrombocytopenic Purpura
- Interventions
- Drug: ARC 1779 PlaceboDrug: ARC1779 Injection
- First Posted Date
- 2008-08-01
- Last Posted Date
- 2009-11-26
- Lead Sponsor
- Archemix Corp.
- Target Recruit Count
- 100
- Registration Number
- NCT00726544
- Locations
- 🇺🇸
Washington University, St. Louis, Missouri, United States
🇮🇹Università Cattolica del Sacro Cuore, Rome, Italy
🇮🇹Fondazione Ospedale Maggiore Policlinico, Milano, Italy
A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of ARC1779 Injection in Patients With Von Willebrand Disease Type 2B
- First Posted Date
- 2008-06-10
- Last Posted Date
- 2009-08-21
- Lead Sponsor
- Archemix Corp.
- Target Recruit Count
- 2
- Registration Number
- NCT00694785
ARC1779 Injection in Patients With Von Willebrand Factor-Related Platelet Function Disorders
Phase 2
Completed
- Conditions
- Purpura, Thrombotic ThrombocytopenicVon Willebrand Disease Type-2b
- Interventions
- First Posted Date
- 2008-03-10
- Last Posted Date
- 2009-01-09
- Lead Sponsor
- Archemix Corp.
- Target Recruit Count
- 28
- Registration Number
- NCT00632242
- Locations
- 🇦🇹
Archemix Investigational Site, Vienna, Austria
Study of ARC1779 in Patients With Acute Myocardial Infarction Undergoing PCI
Phase 2
Terminated
- Conditions
- Acute Myocardial Infarction
- Interventions
- Procedure: PCI
- First Posted Date
- 2007-07-26
- Last Posted Date
- 2009-01-09
- Lead Sponsor
- Archemix Corp.
- Target Recruit Count
- 300
- Registration Number
- NCT00507338
- Locations
- 🇷🇺
Archemix Investigational Site, St. Petersburg, Russia, Russian Federation
Safety, Pharmacokinetics, and Pharmacodynamics of ARC1779 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Thrombosis
- First Posted Date
- 2007-02-08
- Last Posted Date
- 2007-04-20
- Lead Sponsor
- Archemix Corp.
- Target Recruit Count
- 42
- Registration Number
- NCT00432770
- Locations
- 🇺🇸
Bioanalytical Systems, Inc, Baltimore, Maryland, United States
© Copyright 2025. All Rights Reserved by MedPath